000			04746nam a22003975i 4500
001			86571
003			ES-MaUEC
005			20230207040605.0
007			cr nn 008mamaa
008			160310s2016 ja | s |||| 0|eng d
020			_a9784431555889
040			_aES-MaUEC
050		4	_aRC918.G55 _b2016 EB
082	0	4	_a616.61
245	0	0	_aPathogenesis and treatment in IgA nephropathy : _ban international comparison _cedited by Yasuhiko Tomino
250			_a1st ed
260			_aTokyo _bSpringer _c2016
300			_a1 recurso en línea (XI, 342 p.) _b46 ilustraciones, 10 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart I. Pathogenesis -- Chapter 1. Is IgA nephropathy the same disease/a homogenous disease? -- Chapter 2. Genetic variations of IgA nephropathy -- Chapter 3. Is IgA nephropathy a familial or sporadic disease? -- Chapter 4. Heterogeneity of GdIgA1 -- Chapter 5. Differences of histological classification between the Japanese guideline and the Oxford classification -- Chapter 6. Podocyte injury and the role of megalin -- Chapter 7. Complement activation -- Part II. Treatment -- Chapter 8. How different are the current understandings of treatments for IgA nephropathy? -- Chapter 9. Differences in etiology and treatment in China -- Chapter 10. Differences in etiology and treatment in Korea -- Chapter 11. Differences in etiology and treatment in Japan -- Chapter 12. The VALIGA study: Differences in treatment approaches within the EU -- Chapter 13. Differences in etiology and treatment in Scandinavian countries -- Chapter14 The Implication of the KDIGO Clinical Practice Guidelines on management of IgA Nephropathy -- Chapter15 Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines -- Chapter16 Limitations of RAS blockade in IgA nephropathy -- Chapter17 What is the goal for proteinuria in IgA nephropathy? -- Chapter 18. Rationale of tonsillectomy and steroid pulse therapy (TSP): Is it race dependent? -- Chapter 19. Is tonsillectomy a possible treatment for IgA nephropathy from RCT? -- Chapter 20. Is tonsillectomy a possible treatment for IgA nephrology from a retrospective analysis?
520			_aThis book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy (zNephropathy with mesangial IgA-IgG depositsy) as a new disease entity. Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease, with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. However, there are many controversial strategies for the treatment of patients with IgA nephropathy throughout the world, as there are several limitations for treatment in each country. This volume provides nephrologists everywhere with an overview and comparison of both global and regional findings in basic and clinical fields in IgA nephropathy. It covers genetic variation, aberrant IgA1 production, and classification etiology, guidelines, and treatment goals, with all chapters written by top international researchers
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aGlomerulonefritis _9152168 _0comprobar BNE19970947538 _2embne
650		7	_aNefritis _9144292 _0comprobar BNE19912516633 _2embne
650		7	_aUrología _0comprobar BNE19900961422 _2embne _9138565
700	1		_aTomino, Yasuhiko _eeditor literario _9100390 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-55588-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9784431555889
907			_a.b12958499 _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b08-06-17 _cm _dz _eb _feng _gja _h0
945			_aRC918 .G55 P38 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11600081 _z06-04-17
999			_c86571 _d86571 _x1